Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

To gain deeper insights into transcriptomes and epigenomes of organoids, liver organoids from two states (expandable and more differentiated) were subjected to single-cell RNA-seq (scRNA-seq) and single-cell ATAC-seq (scATAC-seq) analyses. Mitochondrial gene expression was higher in differentiated than in non-differentiated hepatocytes, with ATAC-seq peaks increasing near the mitochondrial control region. Differentiation of liver organoids resulted in the expression of transcription factors that act as enhancers and repressors. In addition, epigenetic mechanisms regulating the expression of alpha-fetoprotein (AFP) and albumin (ALB) differed in liver organoids and adult liver. Knockdown of PDX1, an essential transcription factor for pancreas development, led to the hepatic maturation of liver organoids through regulation of AFP and ALB expression. This integrative analysis of the transcriptomes and epigenomes of liver organoids at the single-cell level may contribute to a better understanding of the regulatory networks during liver development and the further development of mature human liver models.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481365PMC
http://dx.doi.org/10.1016/j.isci.2023.107675DOI Listing

Publication Analysis

Top Keywords

liver organoids
20
integrative analysis
8
single-cell rna-seq
8
transcriptomes epigenomes
8
liver
8
organoids
7
single-cell
4
analysis single-cell
4
rna-seq atac-seq
4
atac-seq reveals
4

Similar Publications

Background/aims: Patient-derived organoids (PDOs) are promising preclinical models that replicate critical tumor features. However, intratumoral heterogeneity challenges the clinical utility of PDOs, especially in capturing diverse tumor cell subpopulations.

Methods: Single-cell transcriptomics was used to analyze PDOs from distinct sites within a single gastric cancer tumor, aiming to assess their ability to reflect intratumoral heterogeneity.

View Article and Find Full Text PDF

Background: A decellularized liver scaffold (DLS) is a three-dimensional acellular extracellular matrix created by removing cellular components from liver tissue. Hepatocellular carcinoma (HCC) organoids represent a useful experimental model.

Methods: HCC organoids from patient-derived xenografts (PDX), liver organoids, and HepG2 cells were expanded by cultivation within a murine DLS.

View Article and Find Full Text PDF

Background: Hepatitis D virus (HDV) infection is the most severe form of human viral hepatitis. A poor virus-specific CD8T cell response may result in persistent HDV infection. We investigated anti-viral effect and mechanisms of ubiquitinated small hepatitis D antigen (Ub-S-HDAg) in HBV/HDV superinfected liver organoids.

View Article and Find Full Text PDF

Recapitulating dengue virus infection with human pluripotent stem cell-derived liver organoids for antiviral screening.

Nat Commun

August 2025

State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.

Dengue virus (DENV) poses a major global health threat, affecting an estimated 100 to 400 million people annually. The infection and pathogenesis remain incompletely understood, and no antiviral drug is currently approved for DENV treatment. Here, we develop a human pluripotent stem cell (hPSC)-derived liver organoid (hPLO) model to characterize DENV infection and screen for antivirals.

View Article and Find Full Text PDF

Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids.

Antioxidants (Basel)

July 2025

Department of Internal Medicine, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea.

(1) Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by liver damage similar to alcoholic fatty liver disease, including triglyceride infiltration of hepatocytes, regardless of alcohol consumption. It leads to progressive liver damage, such as loss of liver function, cirrhosis, and liver cancer, and the response rate of drugs under clinical research is less than 50%. There is an urgent need for biomarkers to evaluate the efficacy of these drugs.

View Article and Find Full Text PDF